Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Pharmaceutical
Colorado, USA-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading. 3 April 2025
Pharmaceutical
With two new lawsuits, Eli Lilly has escalated its legal campaign against the makers of unauthorized versions of its diabetes and weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), challenging inroads made by drug compounders in what has become a highly lucrative market. 3 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. 3 April 2025
Pharmaceutical
CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS). 3 April 2025
Pharmaceutical
The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the pharmacological management of moderate-to-severe ulcerative colitis (UC). 2 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Boehringer Ingelheim, now Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its diabetes and lung drugs. 2 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
French drugmaker Sanofi has appointed Chris Corsico as its new global head of development, according to an internal company communication obtained by The Pharma Letter. 2 April 2025
Pharmaceutical
Danish biotech Gubra saw its share gains more than 8% to 448.00 kroner, after it announced positive results from the single ascending dose (SAD) Phase I clinical trial with the long-acting amylin analogue GUBamy (GUB014295). 2 April 2025
Pharmaceutical
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease, that failed to meet the primary endpoint of the study. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
All news
Pharmaceutical
US healthcare giant Johnson & Johnson has announced manufacturing, research and development and technology investments of more than $55 billion in the USA over the next four years. 21 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ oral Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition and the third US indication for the drug. 21 March 2025
Pharmaceutical
US biotech Rhythm Pharmaceuticals has reacquired the rights to its obesity treatment Imcivree (setmelanotide) in China, including Hong Kong and Macau, after terminating a 2021 licensing agreement with China-based RareStone Group. 21 March 2025
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran). 21 March 2025
Pharmaceutical
Japanese ophthalmology company Santen Pharmaceutical announced that it will launch Ryjusea Mini solution 0.025% (tropine sulfate hydrate) on April 21, 2025. 21 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. 20 March 2025
Pharmaceutical
Pharmaceutical leaders are warning that the UK is becoming an unattractive destination for investment due to high and unpredictable levies on medicine sales. 20 March 2025
Pharmaceutical
The Indian subsidiary of US pharma major Eli Lilly (NYSE: LLY) has announced the launch of Mounjaro (tirzepatide) in single-dose vial presentation. This follows the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). 20 March 2025
Pharmaceutical
Purdue Pharma has filed a Chapter 11 Plan of Reorganization and related disclosure statement with the US Bankruptcy Court for the Southern District of New York. 20 March 2025
Pharmaceutical
Whitehawk Therapeutics , formerly Aadi Bioscience, has officially rebranded to reflect its transformation into a pre-clinical-stage biotech focused on antibody-drug conjugates (ADCs). 19 March 2025
Pharmaceutical
Swiss pharma major Novartis is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a restructuring effort ahead of expected generic competition for its top-selling heart failure drug, Entresto (sacubitril/valsartan). 19 March 2025
Pharmaceutical
French independent pharma firm Servier and USA-based Black Diamond Therapeutics, a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors 19 March 2025
Pharmaceutical
Newly-appointed US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has renewed the public health emergency declaration addressing the USA’s opioid crisis, which will allow sustained federal coordination efforts and preserve key flexibilities that enable HHS to continue leveraging expanded authorities to conduct certain activities in response to the opioid overdose crisis. 19 March 2025
Pharmaceutical
Belgium’s largest drugmaker UCB today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year’s MDA Clinical and Scientific Conference, Dallas, Texas. 19 March 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Pharmaceutical
Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD). 18 March 2025
Pharmaceutical
Israeli-headquartered RedHill Biopharma today revealed its plan to submit a UK marketing authorization application (MAA) for Talicia (low-dose rifabutin-triple therapy) for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP). 18 March 2025
Pharmaceutical
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. 18 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze